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Abstract
Spinal cord injury (SCI) is a devastating condition that causes substantial morbidity and mortality and for which no
treatments are available. Stem cells offer some promise in the restoration of neurological function. We used systematic
review, meta-analysis, and meta-regression to study the impact of stem cell biology and experimental design on motor and
sensory outcomes following stem cell treatments in animal models of SCI. One hundred and fifty-six publications using 45
different stem cell preparations met our prespecified inclusion criteria. Only one publication used autologous stem cells.
Overall, allogeneic stem cell treatment appears to improve both motor (effect size, 27.2%; 95% Confidence Interval [CI],
25.0%–29.4%; 312 comparisons in 5,628 animals) and sensory (effect size, 26.3%; 95% CI, 7.9%–44.7%; 23 comparisons in 473
animals) outcome. For sensory outcome, most heterogeneity between experiments was accounted for by facets of stem cell
biology. Differentiation before implantation and intravenous route of delivery favoured better outcome. Stem cell
implantation did not appear to improve sensory outcome in female animals and appeared to be enhanced by isoflurane
anaesthesia. Biological plausibility was supported by the presence of a dose–response relationship. For motor outcome,
facets of stem cell biology had little detectable effect. Instead most heterogeneity could be explained by the experimental
modelling and the outcome measure used. The location of injury, method of injury induction, and presence of
immunosuppression all had an impact. Reporting of measures to reduce bias was higher than has been seen in other
neuroscience domains but were still suboptimal. Motor outcomes studies that did not report the blinded assessment of
outcome gave inflated estimates of efficacy. Extensive recent preclinical literature suggests that stem-cell–based therapies
may offer promise, however the impact of compromised internal validity and publication bias mean that efficacy is likely to
be somewhat lower than reported here.
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Introduction
Stem cells, from which all tissues can be generated, offer the
potential to reconstitute tissues damaged by injury and disease.
However, realising this potential will demand a detailed knowledge
of the genetic and internal environmental cues that specify a cell’s
type, location, and interaction with its neighbours. It will also
require a thorough understanding of stem cell behaviour in the
context of lesioned or damaged tissues.
Stem cell transplantation was pioneered in the 1950s using
haematopoietic stem cells to repopulate the bone marrow in
patients with cancers of the blood and bone marrow [1]. Such is
the success of this approach that an estimated 50,000 of these
transplants are performed each year [2]. As understanding of stem
cell biology has increased, so too has the ambition for restoring
more complex tissues. In animal models, hepatocytes derived from
stem cells can be engrafted into the damaged liver [3], and lineage-
specific stem cells can repair damaged cornea [4,5]. Recent studies
also demonstrate the generation of artificial tissues with key
features of complex solid organs including blood vessels [6], heart
[7–9], lung [10], and kidney [11]. Even in the CNS, where the
breadth of cell types and the complexity of their interactions are
maximal, stem cell implants appear able to integrate into the
existing circuitry [12–14]. In patients, lineage-specific stem cells
have been reported to show efficacy in the regeneration of
craniofacial bones [15] and of damaged cornea [5].
Integration into the host environment and tissue reconstruction
are not the only potentially relevant biological effects of stem cells.
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Immunomodulatory effects of stem cells appear to reduce rejection
of kidney transplants [16,17], corneal allografts [18], and
composite tissue hemi-facial allografts [19]. In the CNS, stem
cells are reported to provide immunomodulatory and neuropro-
tective effects in models of diseases as disparate as retinopathy
[20], neuronal ceroid lipofuscinosis [21], motor neuron disease
[22,23], Parkinson’s disease [24], multiple sclerosis [25,26], stroke
[27–29], and spinal cord injury [30,31].
There is now considerable preclinical literature on the possible
benefits of stem-cell–based therapies following traumatic spinal
cord injury. Stem cells may assist recovery through limitation of
secondary injury, re-myelination, formation of new neuronal
connections, and alteration of the inhibitory environment.
However, it is unclear which type of cells and from what source
are best to implant, how many are needed, whether immunosup-
pression should be used, and whether the implanted cells need to
be modified to enhance particular desirable characteristics. It is
also unclear whether the magnitude of integrative and protective
effects is large enough to be potentially clinically meaningful. We
also do not know whether reports of efficacy in animal models are
potentially biased in favour of positive results.
Here, we report a systematic review, meta-analysis, and meta-
regression of data from controlled in vivo studies testing the efficacy
of stem cells as a treatment in animal models of spinal cord injury.
Our objectives are (i) to establish a summary estimate of the
efficacy of stem cells in animal models of traumatic spinal cord
injury, (ii) to ascertain the conditions under which animal
experiments demonstrate greatest efficacy, and (iii) to determine
any effect of study quality on reported efficacy.
Results
Study Characteristics
Electronic searching identified 156 full publications that met our
prespecified inclusion criteria (Table S1). Forty-five different stem
cell types had been investigated, from which over a third were
derived from adult rats. The duration of experiments following the
induction of SCI ranged from 7 d to 6 mo.
One publication [32] with two individual comparisons involving
36 animals reported the effect of autologous bone marrow stromal
cells on motor score. We included this publication in the overall
assessment of the prevalence of the reporting of measures taken by
the original authors to reduce the risk of bias in their experiments.
However, because this was the only paper to report the effects of
autologous (rather than allogeneic) stem cells, we did not analyse
this further, focussing instead on allogeneic stem cells.
One hundred and fifty-five publications reported the effect of
allogeneic stem cells in 317 individual comparisons; 380 different
motor outcomes were reported and because more than one motor
outcome was reported for some individual comparisons we nested
(see Methods) these into 312 individual comparisons involving
5,628 animals (Figure 1A). Six different tests were used to assess
motor score: the Basso, Beattie and Bresnehan locomotor rating
scale (BBB; [33]), the Basso mouse scale (BMS; [34]), the Tarlov
scale [35], the forelimb placing test [36], the staircase test [37],
and the mouse hind limb motor score [38]. Sixty-one sensory
outcomes were reported; we excluded six outcomes that tested
sensation in unaffected limbs. In 10 outcomes that used the same
test at different intensities in the same cohort of animals, we only
included the median intensity. Therefore, we report data on
sensory outcome reported in 45 experiments nested into 24
comparisons using 473 animals (Figure 1B). In 18 cohorts both
motor and sensory outcomes were reported.
Risk of Bias
We describe the reporting of study quality checklist items
reported for each included publication in Table S2. All studies
included in this analysis came from peer-reviewed papers; while
we identified a number of potentially relevant abstracts, none of
these reported data in sufficient detail to be included. One
hundred and eleven of 156 publications (71%) reported compli-
ance with animal welfare regulations, and 25 (16%) reported
whether or not a conflict of interest existed.
Allocation concealment was reported in 14 of 156 publications
(9%). Random allocation to treatment group (72, 46%) and
blinded assessment of outcome (72, 46%) were reported more
frequently in these publications than in the modelling of other
neurological disorders [39–42], but the reporting of a sample size
calculation (less than 1%) was consistent with the proportions
observed elsewhere (Table 1). No publication reported all four of
these measures to minimise bias.
Despite the reported benefits of hypothermia in SCI [43–45], in
other animal models of neurological disease [46] and in humans
with ischaemic neurological injury [47,48], only 33 (21%) studies
described controlling temperature during the experiments.
There were only sufficient data to assess publication bias in
studies using allogeneic stem cells where outcome was measured as
a motor score. Small study bias was suggested with asymmetry of
the funnel plot (Figure 2A) and Egger regression (Figure 2B) but
not by Trim and Fill.
Meta-Analysis
As expected, our search identified a diverse range of experi-
ments. There was substantial between-study heterogeneity for
studies using allogeneic stem cells both where outcome was
measured as a motor score [heterogeneity (x2) = 9,735, 311
degrees of freedom (df), p,10299; effect size, 27.2% improvement
in outcome [95% confidence interval, 25.0%–29.4%]; 312
comparisons) and as a sensory outcome (x2 = 183, df = 23,
p,10226; effect size, 26.3% [7.9%–44.7%]; 24 comparisons).
Motor score in experiments using allogeneic stem
cells. In meta-regression, eight study characteristics accounted
Author Summary
Spinal cord injury is an important cause of disability in
young adults, and stem cells have been proposed as a
possible treatment. Here we systematically assess the
evidence in the scientific literature for the effectiveness of
stem-cell–based therapies in animal models of spinal cord
injury. More studies reported effects on the ability to move
(‘‘motor outcomes’’) than on sensation (‘‘sensory out-
comes’’). Overall, treatment improves both sensory and
motor outcomes, and for sensory outcome there was a
dose–response effect (which suggests an underlying
biological basis). Although more measures were taken to
reduce the risk of bias than in other areas of translational
neuroscience, unblinded studies tended to overstate the
effectiveness of the treatment. The variability observed
between the studies is not explained by differences in the
stem cells used, but does seem to depend on the different
injury models used to emulate human spinal cord injury.
This suggests that the mechanism of injury should be an
important consideration in the design of future clinical
trials. Furthermore, open questions arise about the use of
immunosuppressive drugs, and efficacy in female animals;
these should be addressed before proceeding to clinical
trial.
Stem Cell-Based Therapy in Spinal Cord Injury
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Figure 1. Summary of data included in meta-analysis of use of stem cells to treat spinal cord injury with individual comparisons
ranked according to their effect on (A) % improvement in motor score and (B) % improvement in sensory score. The shaded grey bar
represents the 95% confidence limits of the global estimate. The vertical error bars represent the 95% confidence intervals for the individual
estimates.
doi:10.1371/journal.pbio.1001738.g001
Table 1. Reporting of study quality criteria.
Item SCI FCI [41] EAE [42] PD [40] AD [39]
Random allocation to group 46% 36% 9% 16% 15%
Blinded assessment of outcome 46% 29% 16% 15% 21%
Sample size calculation 1% 3% ,1% ,1% 0%
Compliance with animal welfare regulations 71% 57% 32% 40% 54%
Statement of a potential conflict of interest 16% 23% 6% 2% 11%
Abbreviations: AD, Alzheimer’s disease; EAE, experimental autoimmune encephalomyelitis; FCI, focal cerebral ischaemia; PD, Parkinson’s disease; SCI, spinal cord injury.
doi:10.1371/journal.pbio.1001738.t001
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for a significant proportion of the between-study heterogeneity in
studies reporting a change in motor score (Table 2). More
influence was apparent for factors related to the lesion model than
those related to stem cell biology. There was no detectable effect of
stem cell dose, derivation (adult or embryonic), manipulation in
culture (genetic, growth factor, antibiotic), number of passages in
culture, method of stem cell selection prior to implantation, route
of administration, frequency of administration, the presence or
absence of a supporting scaffold, time of assessment, anaesthetic
used, or temperature regulation during surgery.
The neurobehavioural test used (Figure 3A) accounted for most
of the observed heterogeneity (adjusted R2 = 12.2%, p,0.00001).
Seventy percent of the data (228 comparisons, 4,042 animals) was
obtained using the BBB locomotor rating scale and suggested an
improvement in outcome of 26.7% (95% CI, 23.9–29.4). Other
tests contributed at most 3.5% of the data; the BMS (10
comparisons, 196 animals) gave results similar to those observed
using the BBB scale (24.5%, 11.2–37.7), while the Tarlov (9
comparisons, 200 animals) and forelimb placing tests (5 compar-
isons, 76 animals) suggested larger effects (73.1%, 57.5–88.7 and
47.9%, 18.8–77.1, respectively). The staircase (1 comparison, 12
animals) and mouse hind limb motor score (3 comparisons, 49
animals) tests reported no significant overall effects. Where
multiple tests were used (in 20% of animals) the detected effect
size was not different to when BBB or BMS were used alone.
Location of injury (Figure 3B) accounted for 10.6% (adjusted
R2, p,0.00001) of the observed heterogeneity, with larger
improvements detected with the most caudal (low thoracic and
lumbar) spinal cord lesions compared with other locations.
Sex accounted for 9.7% (adjusted R2, p,0.00001) of observed
heterogeneity, with efficacy higher in males (27.4%, 21.7–33.1,
1,704 animals) compared with females (22.9%, 19.6–26.3, 2,906
animals). Where sex was not reported and where both sexes were
used (together 18% of the data), substantially higher estimates of
effect size were observed (Figure 3C).
Efficacy was lower when immunosuppression was used (adjusted
R2 = 5.8%, p,0.005). For cyclosporine A [78 comparisons, 1,242
(22% of total) animals], efficacy was 19.6% (13.7–25.4) compared
with 30.2% (27.2–33.1) in 226 comparisons and 4,259 animals
where no immunosuppression was used. Efficacy also appeared
smaller in a small number of experiments [6 comparisons, 80
(1.4%) animals] using FK506 (Figure 3D).
The approach used to induce injury had a smaller but
significant effect (adjusted R2 = 3.4%, p,0.01, Figure 3E). The
most common approach was contusion injuries [149 comparisons,
2,847 animals; 23.8% improvement, (20.1–27.5)] with compres-
sive approaches providing improvements of a similar magnitude
[59 comparisons, 1,135 animals; 25.8% (18.8–32.8)]. Slightly
higher estimates of effect size were obtained when the cord had
been transacted [65 comparisons, 928 animals; 30.5% (24.1–37.0)]
or hemisected [38 comparisons, 717 animals; 37.6% (29.1–46.2)].
Efficacy was highest with treatment strategies using cell lines
(7 comparisons, 131 animals) rather than primary cells, and
amongst primary cells those derived from mice were the least
effective (Figure 3F, adjusted R2 = 4.3%, p,0.005).
Efficacy was lower in studies reporting the blinded assessment of
outcome [147 comparisons, 2,653 animals, 23.6% (18.5–28.7)]
than in those that did not [165 experiments, 2,975 animals, 30.3%
(26.9–33.8); Figure 3G; adjusted R2 = 2.2%, p,0.01]. No effect
was seen for reporting of allocation concealment, randomisation,
or sample size calculations.
Motor score subanalyses. A large proportion of the data
(115 comparisons, 2,165 animals) were obtained from rats
implanted with allogeneic stem cells, after injury created with an
impactor, at the midthoracic level and assessed by the BBB test,
where the sex of the animal was explicitly stated. This large and
experimentally homogeneous subset of the data was analysed
separately to establish whether a clearer picture of the key
determinants of stem cell biology and implantation emerged.
Heterogeneity was reduced from 9,735 (x2) over 312 individual
comparisons to 1,420 over 115 comparisons, confirming the
validity of this approach. As in the full analysis, stem cell dose,
number of passages during culture, the presence of additional
antibiotics or growth factors in the culture medium, selection
methodology, the use of adult or embryonic stem cells and the
species of origin, route of administration, presence of a supporting
scaffold, and prior differentiation or transfection of the stem cells
had no significant effect.
In this subpopulation of comparisons (Table 3) the anaesthetic
used accounted for a high proportion of the heterogeneity
(adjusted R2 = 16.3%, p,0.001). Isoflurane was infrequently used
(3 comparisons, 47 animals) and was associated with the largest
improvement in outcome. Of the most commonly used anaes-
thetics, chloral hydrate [21 comparisons, 417 animals, 33.0%
(16.0–50.1)] was associated with the largest effect size (Figure 4A).
Figure 2. Assessment of publication bias shown with (A) Funnel
plot and (B) Egger regression.
doi:10.1371/journal.pbio.1001738.g002
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The interval from lesioning to outcome assessment accounted
for 11.0% of the heterogeneity such that absolute effect size fell by
1.7% for every additional week of delay to outcome assessment.
The presence of immunosuppression also accounted for a large
proportion of the heterogeneity in this constrained dataset
(adjusted R2 = 10.4%, p,0.01); both cyclosporine A and FK506
substantially reduced the benefit derived from stem cells
(Figure 4B). BBB scores were lower in experiments where other
tests had also been reported [22 comparisons, 473 animals, 14.0%
(4.7–23.3)] than where BBB was reported alone [93 comparisons,
Table 2. Study characteristics accounting for heterogeneity of motor score.
Motor Score Effect size % (95% CI)
Number of
Animals
Number of
Comparisons Adjusted R2 p,
Pooled estimate 27.2 (25.0–29.4) 5,628 312
NBS Motor tests 28.1 (237.7–21.4) 49 3 12.24% 0.00001
Staircase 22.0 (243.3–39.3) 12 1
BMS 24.5 (11.2–37.7) 196 10
Multiple tests 24.5 (17.8–31.2) 1,053 56
BBB 26.7 (23.9–29.4) 4,042 228
Forelimb placing test 47.9 (18.8–77.1) 76 5
Tarlov 73.1 (57.5–88.7) 200 9
Location of injury Cervical 32.2 (12.2–52.3) 156 13 10.64% 0.00001
Lowerthoracic/lumbar 48.1 (39.7–56.5) 456 28
Midthoracic 24.9 (22.3–27.5) 5,016 271
Sex Female 22.9 (19.6–26.3) 2,906 171 9.69% 0.00001
Male 27.4 (21.7–33.1) 1,704 87
Unknown 35.7 (27.9–43.5) 676 37
Both 48.7 (37.6–59.7) 341 17
Immunosuppression Cyclosporine A/MP 211.5 (292.5–69.5) 12 1 5.83% 0.0026
FK506 11.6 (28.0–31.2) 80 6
Cyclosporine A 19.6 (13.7–25.4) 1,242 78
None 30.2 (27.2–33.1) 4,259 226
Cyclophosphamide 44.4 (20.8–89.7) 36 1
Method used to induce SCI Impactor with spacer 11.6 (211.3–34.5) 79 5 4.40% 0.0115
Aneurysm clip 18.7 (7.9–29.4) 356 20
Impactor 24.1 (20.4–27.8) 2,768 144
Unknown 27.8 (19.7–36) 665 35
Balloon compression 28.4 (15.8–41.1) 235 14
Compression weight 30.1 (20.3–39.9) 544 25
Blade 33.5 (26.4–40.6) 682 52
Scissors 42.5 (30–54.9) 278 16
Filament 79.2 (4.8–53.6) 20 1
Source of cells Cell line 41.1 (25.1–57.1) 131 7 4.34% 0.0034
Human 28.0 (21.6–34.3) 1,483 77
Mouse 18.0 (11.2–24.8) 877 56
Rat 29.2 (25.9–32.6) 3,136 172
Type of injury Contusion 23.8 (20.1–27.5) 2,847 149 3.44% 0.0073
Compression 25.8 (18.8–32.8) 1,135 59
Transection 30.5 (24.1–37)) 928 65
Hemisection 37.7 (29.1–46.2) 717 38
Blinded assessment of outcome Not blinded 30.3 (26.8–33.8) 2,975 165 2.21% 0.01
Blinded 23.6 (18.5–28.7) 2,653 147
doi:10.1371/journal.pbio.1001738.t002
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1,692 animals, 25.1% (21.0–29.1); Figure 4C, adjusted R2 = 5.0%,
p,0.02]. There was no impact of whether stem cells were given
once, at multiple times, or by continuous infusion; the sex of the
animals; or the reporting of randomisation, allocation conceal-
ment, or blinded assessment of outcome.
A second subanalysis of the motor dataset was performed to
examine whether restriction of the analysis to higher quality
studies appreciably altered the results. This analysis was
hampered by the paucity of truly high-quality data. None of
the contributing papers reported each of four key measures of
internal validity (randomisation, blinded assessment of outcome,
allocation concealment, and sample size calculation), and only
20 individual comparisons came from papers describing three
of the four. As a compromise we analysed the 25% of the
Figure 3. Study characteristics which account for heterogeneity of total motor dataset. (A) Behavioural test used, (B) location of injury, (C)
sex of animals, (D) immunosupressant used, (E) type of Injury, (F) stem cell source, and (G) effect of blinding. The shaded grey bar represents the 95%
confidence limits of the global estimate. The vertical error bars represent the 95% confidence intervals for the individual estimates.
doi:10.1371/journal.pbio.1001738.g003
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motor dataset that reported having both randomisation and
blinding.
Restricting the analysis in this way reduced the number of
animals assessed from 5,628 to 1,466 and heterogeneity fell from
9,735 to 945 (x2). Despite this, the key features of both the full and
the subanalysis are the same. The characteristics of the animal
model still have more impact than the type of cells implanted
(Tables 2 and 4).
Immunosuppression no longer has an effect on heterogeneity
and the effect size in animals immunosuppressed with cyclospor-
ine-A [mean, 24.3; 95% CI, 13.2–35.3] is the same as in animals
where immune suppression is not used (mean, 24.9; 95% CI, 18.3–
31.6). Allocation concealment emerges as significant, though not
in the expected direction. Also the type of cell culture medium and
type of cell manipulation prior to implantation also begin to have
an impact, but it should be noted that in both cases it is the
experiments where the precise conditions are ‘‘unknown’’ that
report the greatest effect. In the subanalysis, the mean number of
cells implanted is substantially lower than in the full analysis
(6.36105 versus 7.46108), and a dose–response relationship is
evident.
Sensory score in experiments using allogeneic stem
cells. While motor behaviour was relatively unaffected by most
factors specific to stem cell biology, the reverse was true for studies
reporting a change in sensory outcome (Table 5).
Of the five study characteristics accounting for a significant
proportion of the between-study heterogeneity, the type of
manipulation in culture had the largest effect (adjusted
R2 = 61.3%, p,0.005). Prior differentiation was associated with
larger effect sizes, while transfection was associated with smaller
effects (Figure 5A). The number of cells administered had a clear
dose–response effect (adjusted R2 = 31.7%, p,0.02; Figure 5B).
Studies that delivered cells intravenously were associated with
significantly larger effects than studies transplanting the cells
directly into the lesion area of the spinal cord (adjusted
R2 = 19.2%, p,0.05) (Figure 5C).
As with the motor score subanalysis, the anaesthetic agent had a
large effect (adjusted R2 = 42.8%, p,0.05). The use of isoflurane
to induce anaesthesia in three individual comparisons was
associated with substantial additional benefit compared to other
methods of anaesthesia (Figure 5D). All studies assessed sensory
outcome in either all male or all female cohorts, with studies using
female animals appearing to offer no benefit (Figure 5E; adjusted
R2 = 21.5%, p,0.05).
Discussion
Systematic review and meta-analysis have helped identify biases
within clinical trials [49], providing an impetus to improve
standards [50]. This approach offers similar benefits for animal
studies [28,41,51] by describing the impact of biological and
experimental factors on reported efficacy in a systematic and
transparent summary of all available data. This allows judgement
of the extent to which conclusions are at risk of bias [52]. In this
study we apply these techniques to provide a detailed systematic
analysis of the animal literature describing stem-cell–based
therapies in spinal cord injury.
Overall, treatment with allogeneic stem cells improves both
motor and sensory outcome after spinal cord injury by around
25%, but with important differences between the two datasets.
Because of the amount of data, conclusions relating to motor
outcome (5,628 animals) are probably more robust than those
relating to sensory outcomes (473 animals). For both outcomes
there was a broad range of experimental approaches, reflected in
the high levels of heterogeneity seen. This is typical for systematic
reviews in animal studies and validates our choice of a random
effects model, and our summary estimates should be considered
as the average efficacy rather than the best estimate of a single
‘‘true’’ efficacy. Interestingly, improvement in sensory outcome
seems to be sensitive to differences in factors relating to treatment
(i.e., stem cell biology), while motor outcome appears to be more
sensitive to factors relating to the lesion and the outcome measure
used, and to be less dependent on the biological features of the
stem cells used.
Evidence supporting a dose–response relationship for sensory
outcome suggests the presence of a biologically plausible effect. We
Table 3. Study characteristics accounting for heterogeneity of motor score subanalysis.
Motor Score
Effect Size %
(95% CI)
Number of
Animals
Number of
Comparisons Adjusted R2 p,
Pooled estimate 24.1 (20.1–28.1) 2,165 115
Anaesthetic Halothane 15.5 (0.3–30.8) 147 6 16.3% 0.0007
Ketamine 17.4 (0.6–34.2) 508 31
Pentobarb 17.5 (1.1–33.9) 740 39
Unknown 28.8 (10.8–46.8) 265 13
Chloral Hydrate 33.0 (16.0–50.1) 417 21
Isoflurane 59.2 (31.8–86.7) 47 3
Time of assessment 21.7(22.8 to 20.6) for each 1 week delay in assessment 11.0% 0.002
Immunosuppression FK506 11.8 (26.0–29.5) 80 6 10.42% 0.0064
Cyclosporine A 16.5 (9.0–24.0) 675 40
None 27.8 (23.1–32.4) 1,410 69
NBS Multiple 14.0 (4.7–23.3) 473 22 5.0% 0.02
BBB 25.1 (21.0–29.1) 1,692 93
doi:10.1371/journal.pbio.1001738.t003
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observed that prior differentiation of the implanted cells was
associated with larger effects. Where the influence of cell
differentiation was formally studied, a relationship with outcome
was observed [53]. This suggests that optimal efficacy might be
seen when cells have some lineage specificity but before final cell
type commitment has occurred. For sensory outcome, studies
where cells were delivered intravenously, rather than directly into
the injured spinal cord, were associated with significantly larger
effects. This suggests either that systemic changes may mediate the
effects of stem cells or that local implantation may create
additional injury that masks the benefit provided by stem cells.
We did not see a dose–response relationship for motor
outcomes, even where we limited our analysis to a more
homogenous subset of experiments. It may be that there is no
dose–response effect or that the doses used in these experiments
were all large enough to generate maximal responses. Where dose
response was formally studied the authors found increasing benefit
from doses as low as 10,000 implanted cells [54], and the median
number of implanted cells in comparisons reporting motor
outcomes was 250,000.
Immunosuppression with cyclosporine A was associated with
increased efficacy in a systematic review of stem cells in focal
cerebral ischaemia [28], and it is therefore interesting that in
spinal cord injury both cyclosporine A and FK506 are associated
with reduced efficacy. This suggests that any beneficial effect of
immunosupressants in promoting the survival of transplanted cells
is outweighed by other factors, such as effects on stem cell biology
or intrinsic repair mechanisms. Unfortunately, because of the
univariate nature of our analyses we are unable to determine a
‘‘benefit–risk ratio’’ for the use of immunosuppression. However,
there are studies that indicate that bone-marrow–derived stem
cells are able to produce compartmentalised inflammatory
lesions [55,56]. The mechanisms behind this observation are
not understood, yet there are rising concerns that unwanted
Figure 4. Study characteristics that account for heterogeneity of motor data subanalysis when only data from rats implanted with
allogeneic stem cells after injury created with an impactor at the midthoracic level and assessed by BBB. (A) Anaesthetic used, (B)
immunosupressant used, and (C) influence of additional behavioural testing on BBB. The shaded grey bar represents the 95% confidence limits of the
global estimate. The vertical error bars represent the 95% confidence intervals for the individual estimates.
doi:10.1371/journal.pbio.1001738.g004
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inflammatory-driven side effects, such as neuropathic pain, might
limit the ‘‘usefulness’’ of gained motor function.
For motor outcome, the neurobehavioural test used (Figure 3A)
accounted for most of the observed heterogeneity. The BBB
locomotor rating scale was used in 70% of animals. In the more
focussed analysis of rat allogeneic, midthoracic impact injury,
using BBB as an outcome, studies that used other behavioural tests
in addition to the BBB reported smaller effect sizes for the BBB.
This may be a manifestation of outcome reporting bias; if the
outcome on the BBB is smaller than expected, investigators might
also report the outcome on other tests where the effect was larger;
if the effect measured using the BBB was considered ‘‘sufficient,’’
there might be less motivation also to report outcomes using other
measures, particularly if these were smaller than seen using the
BBB.
Overall, there was no improvement in motor outcome where
this was assessed using the staircase or mouse hind limb motor
score tests. However, these accounted for a small proportion of the
Table 4. Study characteristics accounting for heterogeneity of motor score—Randomised and blinded subset.
Motor Score Effect Size % (95% CI)
Number of
Animals
Number of
Comparisons Adjusted R2 p,
Pooled estimate 24.7(20.2–29.3) 1,466 79
Method used to
induce SCI
Aneurysm clip 21.7 (244.3–40.9) 18 2 41.2% 0.0000001
Balloon compression 19.8 (0.1–39.4) 79 6
Compression, weight 21.9 (8–35.8) 253 8
iridesctomy scissors 57.6 (40.2–75) 115 5
Impactor 14.6 (7.9–21.3) 680 34
Knife 42 (29.2–54.8) 169 11
Unknown 23.1 (11.2–35) 152 13
Type of injury Compression 20.2 (7.2–33.2) 350 16 25.46% 0.0007
Contusion 14.7 (7.4–21.9) 680 34
Hemisetion 41.1 (27.354.9) 240 12
Transection 32.9 (21.1–44.8) 196 17
Location of injury LowerThoracic/Lumbar 53.8 (37.9–69.7) 78 7 23.68% 0.000001
Midthoracic 21.3 (16.4–26.2) 1,388 72
NBS BBB 24.2 (19.1–29.3) 1,165 66 22.51% 0.0002
Multiple tests 15.2 (2.1–28.4) 241 11
Tarlov 84.5 (54.7–114.3) 60 2
Dose 7.08 (3.52–1.06) for each additional million cells 21.85% 0.000001
Sex Both 53.8 (37.2–70.4) 78 7 21.28% 0.0015
Female 21 (14.6–27.4) 813 43
Male 22.6 (12.3–32.8) 553 28
Unknown 3.2 (239.2–45.6) 22 1
Allocation
concealment
Concealed 37.1 (26.3–47.9) 368 20 2.21% 0.01
Not concealed 19.4 (13.7–25.1) 1,098 59
Cell culture medium Antibiotic+Growith Factor 23.2 (7.4–39.1) 240 13 10.84% 0.031
Growth Factor 19.2 (12–26.3) 663 36
Other 26 (14.4–37.7) 479 22
Unknown 44.1 (27.7–60.6) 84 8
Cell manipulations Differentiation 10.4 (23.1–23.9) 33 17 10.26% 0.0224
Diff.+Transfection 19.7 (28.8–48.3) 33 2
None 27.3 (19.1–35.6) 646 28
Transfection 22.8 (8.9–36.7) 272 18
Unknown 36 (22.4–49.6) 193 14
doi:10.1371/journal.pbio.1001738.t004
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overall dataset, and so these results should be interpreted with
caution.
Efficacy was strongly associated with both the location of and
the methodology used to create the injury. The largest effect was
seen with lower thoracic and lumbar lesions and when the spinal
cord was lesioned by hemisection or transsection rather than
contusion or compression.
The use of isoflurane anaesthesia at SCI induction was
associated with substantial improvement in sensory outcome; in
the overall motor analysis, there was no effect, but in the more
homogenous restricted analysis, isoflurane was again associated
with substantially larger effects. Again, this contrasts with findings
in focal cerebral ischaemia and suggests that, despite interest in a
general paradigm of ‘‘neuroprotection,’’ these conditions are in
certain respects biologically very different. However, these findings
are based on a small number of individual comparisons and should
be interpreted with caution.
The sex of the experimental animal accounted for a large
proportion of the observed heterogeneity in both the sensory and
motor analyses. For the motor analyses, this seems to be the
influence of abnormally high effect sizes reported in studies where
either the sex of the animals used was not reported or where ‘‘both
sexes’’ were used. For sensory outcome, studies using male animals
led to significantly higher estimates of effect with no clear benefit
detected in female animals.
Thirty percent of animals in our dataset were treated with
stem cells at the time of injury. Although this may be helpful in
the biological assessment of stem cell therapies, it is of limited
clinical relevance. The time of administration, although impor-
tant with regard to translation to a clinical setting, had no
significant impact on the effects reported. This appears to be
somewhat unlikely, and our findings may mask different efficacies
of different stem cell approaches at different times—those with
more neuroprotective characteristics perhaps being more effec-
tive when given early, and those with more influence on
neuroregeneration and repair being more effective when given
late.
We found that the prevalence of reporting of randomisation and
blinded assessment of outcome was higher than that reported in
the modelling of other neurological disorders, suggesting more
rigour in the conduct of these studies [39–42]. Other markers of
internal validity, such as sample size calculations, were rarely
reported (Table 1). The lack of an a priori sample size calculation
increases the risk that group sizes were increased during the
experiment, in light of analysis showing borderline nonsignificant
results; this is an important potential source of bias. It is of course
possible that some authors had taken measures to reduce bias but
did not report them; this underlines the importance of reporting
guidelines [57,58].
For the larger motor dataset, both publication bias (Figure 2B)
and failure to report blinding (Figure 3H) were both associated
with a significant overestimation of overall effect size; there was no
apparent impact of a failure to report randomisation. In the Egger
regression (Figure 2B) removal of the two most extreme data points
did not change the interpretation that publication bias was present
(not shown).
Stratification of the data to determine the effect of the above
facets of experimentation is desirable. However, no publication
randomised, blinded assessment of outcome, concealed allocation,
and performed a sample size calculation and only 20 individual
comparisons came from papers describing three of the four.
Therefore, we subanalysed the 25% of the motor dataset that
reported having both randomised and blinded.
In this subanalysis the characteristics of the animal model still
have more impact than the type of cells implanted. However, there
were differences, but the reductionist approach of this subanalysis
does raise the possibility that these might be false positives due to
loss of power. The type of cell culture medium and type of cell
manipulation prior to implantation appear to have an impact, but
it should be noted that in both cases it is the experiments where the
Table 5. Study characteristics accounting for heterogeneity of sensory score.
Sensory Outcome Effect Size % (95% CI)
Number of
Animals
Number of
Comparisons Adjusted R2 p,
Pooled estimate 26.3 (7.9–44.7) 473 23
Cell manipulation Differentiation 79.9 (34.8–125) 156 3 61.27% 0.0049
Transfection 12.1 (223.1–47.3) 131 8
None 42.5 (12.7–72.3) 156 10
Unknown 0.0 (243.5–43.5) 30 2
Anaesthetic Isoflurane 81.0 (37.0–125.1) 161 3
Ketamine 12.9 (211.3–37.1) 131 11
Pentobarbital 17.5 (216.7–51.8) 104 5 42.79% 0.048
Halothane 215.3 (2318.1–287.5) 24 2
Unknown 17.7 (253.7–89) 53 2
Dose 27.8 (5.6–50.0) for each increment of 16106cells 31.72% 0.017
Sex Male 39.7 (3.9–75.4) 347 11 21.48% 0.03
Female 20.3 (229.5–28.9) 126 12
Route of delivery Intraspinal cord 20.4 (2.5–38.4) 428 21 19.25% 0.046
Intravenous 77.2 (21.6–132.8) 45 2
doi:10.1371/journal.pbio.1001738.t005
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Figure 5. Study characteristics that account for heterogeneity in sensory score. (A) Type of manipulation of stem cells prior to
implantation, (B) dose–response relationship, (C) route of stem cell delivery, (D) anaesthetic used, and (E) sex. The shaded grey bar represents the 95%
confidence limits of the global estimate. The vertical error bars represent the 95% confidence intervals for the individual estimates.
doi:10.1371/journal.pbio.1001738.g005
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precise conditions are ‘‘unknown’’ that report the greatest effect.
There is no obvious biological explanation for this. It may be that
a failure to report such details is a surrogate indication that such
work is generally of lower quality, and therefore at greater risk of
bias.
Immunosuppression is no longer identified as accounting
for a significant proportion of the heterogeneity. However,
the effect size in cyclosporine-A–treated animals (mean, 24.3;
95% CI, 13.2–35.3) is the same as in animals where no
immune suppression was used (mean, 24.9; 95% CI, 18.3–31.6).
This appears to confirm that immune suppression offers no
advantage in experiments using allogeneic implants to treat
SCI.
Intriguingly, in the subanalysis a dose–response relationship
does emerge. As the mean number of cells implanted is 6.36105
rather than 7.46108 in the full motor dataset, this is consistent
with the hypothesis that such an effect was previously masked by a
ceiling effect.
Limitations of our approach. Firstly, we were only able to
include data from studies in the public domain and—for motor
outcome at least—there is evidence of a publication bias in favour
of studies with large effect sizes. Further, we found some evidence
(in the motor BBB subanalysis) consistent with selective reporting
of outcomes within individual publications. The true effect sizes
are therefore likely to be lower than reported here. Secondly, for
both study quality and study design features, we relied on
published information. Where relevant information was not
available (the sex of a cohort of animals, or the taking of measures
to reduce bias), we have either analysed these as not known or
inferred that things that were not reported did not occur. Thirdly,
we present a series of univariate analyses; multivariate meta-
regression or stepwise partitioning of heterogeneity might provide
more robust insights, but these techniques are not well established.
Similarly, for continuous variables, the meta-regressions reported
here assumed a linear relationship between the independent and
dependent variables, and this is likely that this represents an
oversimplification, at least for some independent variables.
Fourthly, we have observed the experiments of others rather than
conducted experiments of our own, and this observational
research should be considered as hypothesis generating only.
Finally, we limited our analysis to neurobehavioural outcomes; the
greater benefit seen in hemisected and transsected lesions
compared with compressive of contusional injuries may have
important histological correlates, and this is worthy of further
exploration.
In conclusion, stem cells appear to have substantial efficacy in
animal models of traumatic SCI. Effects on sensory outcome
appear more dependent on facets of stem cell biology: motor
outcome appears to be more dependent on features of the animal
modelling and the outcome scale used.
Methods
The study protocol is available at www.camarades.info/
index_files/Protocols.html. A completed PRISMA checklist and
flow diagram for this systematic literature review can be found in
Text S1.
Definitions
We define a ‘‘publication’’ as a discrete piece of work (including
abstracts); each publication may report data from a number of
experiments. Each experiment may describe outcome in a number
of different experimental cohorts, and the contrast between
outcomes in a single treatment cohort with that in a control
cohort we define as an ‘‘individual comparison.’’ We define
‘‘nesting’’ as combining the effect sizes from different functional
outcomes measured in the same cohort of animals to give a single
summary estimate of effect in that individual comparison (a nested
individual comparison).
Systematic Review
Using prespecified inclusion and exclusion criteria we identified
all publications reporting relevant experiments (see below) by
searching (December 2011) three electronic databases (PubMed,
EMBASE, and ISI Web of Science) using the search strategy
‘‘(stem cell OR stem OR haematopoietic OR mesenchymal) AND
(spinal cord injury OR hemisection OR contusion injury OR
dorsal column injury OR complete transection OR corticospinal
tract injury),’’ with search results limited to those indexed as
describing animal experiments.
Inclusion and Exclusion Criteria
Two investigators (A.A. and E.S.) independently reviewed
retrieved publications. We included experiments where functional
outcome in a group of animals exposed to traumatic spinal cord
injury and treated with allogeneic or autologous stem cells was
compared with functional outcome in a control group of animals.
We excluded individual comparisons that did not report (or where
we could not calculate) the number of animals, the mean outcome,
or its variance in each group. We excluded experiments where
interventions such as growth factors were used to mobilise
endogenous stem cells or where nontraumatic models of spinal
cord injury were used.
Data Extraction
From each individual comparison we extracted data for
reported outcomes. This included extraction of mean and
variance data from each cohort exposed to an intervention
(controls and active therapy) and from sham cohorts of normal
(unlesioned and untreated) animals, and by imputation where the
performance of a normal animal could be imputed from the
description of the scoring scale. Stem cells were characterised as
‘‘autologous’’ where cells were extracted from an animal, might
be manipulated in some way, then returned to the same animal;
or ‘‘allogeneic’’ where embryonic or adult cells derived from a
different animal were administered to a recipient animal. Where
a publication reported more than one experiment, or where an
experiment reported more than one individual comparison (for
instance, increasing numbers of stem cells transplanted), we
considered these separately and extracted data for each,
correcting the weighting of these studies in meta-analysis to
reflect the number of experimental groups served by each
control group. Where different functional outcomes were
reported in a single cohort of animals, we combined these
outcomes using fixed effects meta-analysis (nesting), to give a
summary estimate of functional outcome in that cohort,
described here as a comparison. Where a test involved exposing
the animal to increasing intensities of the same stimulus (for
instance, in allodynia testing), we used data for the median
intensity. For sensory tests, only data for stimulation distal to the
lesion were included. Where functional outcome was measured
at different times, we extracted data for the last time point
reported.
Study quality was assessed using a checklist adapted from good
laboratory practice guidelines for in vivo stroke modelling [59] and
the CAMARADES quality checklist [60]. The checklist comprised
(i) publication in a peer-reviewed journal, (ii) statements describing
control of temperature, (iii) randomisation to treatment group, (iv)
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allocation concealment, (v) blinded assessment of outcome, (vi)
avoidance of anaesthetics with known marked intrinsic neuropro-
tective properties, (vii) sample size calculation, (viii) compliance
with animal welfare regulations, and (ix) whether the authors
declared any potential conflict of interest.
Analysis
For each individual comparison, we calculate a normalised
effect size [normalised mean difference) as the percentage
improvement (‘‘+’’ sign) or worsening (‘‘2’’ sign) of outcome in
the treatment group using the following formula:
ESi~100%|
xc{xshamð Þ{ xrx{xshamð Þ
xc{xshamð Þ ,
where xc and xrx are the mean reported outcomes in the control
and treatment group, respectively, and xsham is the mean outcome
for a normal (unlesioned and untreated) animal. In this
calculation, the score achieved by the sham animals acts as the
‘‘fixed zero value’’ or baseline allowing the difference between the
sham and treatment groups to be expressed as a ratio. This ratio
takes into account differences in the ‘‘direction’’ of individual
neurobehavioural scales.
Its corresponding standard error was calculated using:
SEi~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SD2
c
nc
z
SD2
rx
nrx
s
,
where nc refers to the number of animals in the control group and
nrx refers to the number of animals in the treatment group. SD
2
c
and SD2rx are the normalised standard deviations for the control
and treatment group, respectively. These were calculated using the
formulae:
SDc~100|
SDc
xc{xsham
and SDrx~100|
SDrx
xrx{xsham
,
where SDc and SDrx are the reported standard deviation for the
control and treatment group, respectively.
We then used DerSimonian and Laird random effects weighted
mean difference meta-analysis to calculate a summary estimate of
effect size; results are presented as the percentage improvement in
outcome and its 95% confidence intervals. The variability of the
outcomes assessed is presented as the heterogeneity statistic (x2)
with n21 degrees of freedom.
The analysis was stratified according to (i) the approach to stem
cell therapy (allogeneic, autologous, embryonic, source of cells,
ex vivo manipulation), (ii) biological factors (number of cells,
time and route of administration, time of assessment of outcome),
(iii) aspects of study design (anaesthesia, species of animal,
immunosuppression, model and severity of spinal cord injury),
and (iv) elements of study quality.
The extent to which study design characteristics explained
differences between studies was assessed using meta-regression
with the metareg function of STATA/SE10, and the significance
level was set at p,0.05. The meta-regression was univariate rather
than multivariate; and we calculated adjusted R2 values (a
measure of how much residual heterogeneity is explained by the
model) to explain the proportion of the observed variability in the
observed effect size for a group of experiments explained by
variation in the independent variable in question [61].
We sought evidence of publication bias using a funnel plot,
Egger regression, and Trim and Fill [62]. A detailed description of
the statistical methods used for meta-analysis and meta-regression
can be found in [63].
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